Author:
Trilisnawati Damai,Diba Sarah,Kurniawati Yuli,Nugroho Suroso Adi,Rusmawardiana Rusmawardiana,Pamudji Raden
Abstract
Background: Male androgenetic alopecia (MAGA), also known as androgenetic alopecia, is the most common hair loss in males who have a genetic predisposition. The pattern of baldness in MAGA starts from the frontal area in a triangular pattern, followed by progressive thinning of the vertex until baldness occurs. Generally, the diagnosis of MAGA is established by clinical examination. FDA has approved a combination of topical minoxidil and oral finasteride for MAGA treatment. Currently, there is another treatment option like dutasteride, a prostaglandin analog, ketoconazole, and co-adjuvant therapy like laser therapy, hair transplantation, and so on. Purpose: To provide an updated treatment for MAGA. Review: Etiopathogenesis of MAGA is influenced by genetic susceptibility and hormonal factors. The European Consensus Group set the evaluation diagnosis of MAGA to include a historyof hair fall, physical examination, hair examination, supporting examination, and clinical documentation. There are therapeutic options for MAGA, including antiandrogen therapies, androgen-independent therapies, and co-adjuvant therapies. The FDA has approved a combination of topical minoxidil and oral finasteride for MAGA treatment. MAGA may affect patients’ quality of life and self-esteem. In general, patients expect higher. Conclusion: MAGA is the most common progressive hair loss in males. The MAGA therapy is expected to achieve cosmetically significant regrowth and to slow additional hair loss.
Reference32 articles.
1. Blume U, Kanti V. Disorders of hair and nails. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick's Dermatology in General Medicine. Chicago: McGraw-Hill Company; 2019. p. 495-1506.
2. Sperling L, Sinclair R, Shabrawi L. Alopecias. In: Bolognia J, Schaffer V, Cerroni L, editors. Dermatology. 4th ed. London: Elsevier; 2018. p. 1162-85.
3. Sinclair RD. Male androgenetic alopecia. Expert Opin Pharmacother 2010;1(4):319-27.
4. Androgenetic alopecia: a review;Lolli;Endocrine,2017
5. Androgenetic alopecia: an update of treatment options;Kelly;Drugs,2016